Rapid Infusion Rituximab for Maintenance Therapy : Is It Feasible?

Abstract EN

Rituximab is an anti-CD-20 monoclonal antibody used in the management of lymphoproliferative disorders.

The use of maintenance rituximab has improved progression free survival and overall survival in follicular lymphomas.

Although rapid rituximab infusions have been studied extensively, there is little data on the use of rapid infusions during maintenance therapy for low grade lymphomas.

The primary objective of this retrospective analysis was to evaluate the incidence of Grade 3 and 4 toxicities with maintenance rapid infusion rituximab according to the Common Terminology Criteria for Adverse Events version 4 (CTC v.

4).

Secondary objectives included evaluating all grade infusion related adverse events and correlation of adverse events with varying schedules of rituximab maintenance therapy.

All patients who received rapid infusion rituximab as maintenance therapy for low grade lymphoma between December 2007 and November 2011 were included.

Rapid rituximab infusions were administered over 90 minutes.

Demographic, laboratory and clinical data were collected.

A total of 109 patients received 647 rapid rituximab infusions.

Three patients experienced an adverse reaction which resulted in one grade 1 infusion reaction and three grade 3 infusion reactions.

No patients required hospitalization.

All 3 patients received pharmacological and/or supportive care to relieve symptoms associated with the reaction.